SEOUENCE LISTING



SATO, Noriyuki TORIGOE, Toshihiko HARIU, Hiroyuki HIROHASHI, Yoshihiko

HLA-A24 BINDING CANCER ANTIGEN PEPTIDE DERIVED FROM LIVIN

<130> 0020-5461PUS1

<140> US 10/563,916

<141> 2006-01-10

<150> PCT/JP04/10008

<151> 2004-07-07

<150> JP2003-273236

<151> 2003-07-11

<160> 63

<170> PatentIn version 3.2

<210> 1

<211> 280

<212> PRT

<213> Homo sapiens

<400> 1

Met Gly Pro Lys Asp Ser Ala Lys Cys Leu His Arg Gly Pro Gln Pro 1 $$ 5 $$ 10 $$ 15

Ser His Trp Ala Ala Gly Asp Gly Pro Thr Gln Glu Arg Cys Gly Pro 20 25 30

Arg Ser Leu Gly Ser Pro Val Leu Gly Leu Asp Thr Cys Arg Ala Trp 35 40 45

Asp His Val Asp Gly Gln Ile Leu Gly Gln Leu Arg Pro Leu Thr Glu 50 60

Glu Glu Glu Glu Gly Ala Gly Ala Thr Leu Ser Arg Gly Pro Ala 65 70 75 80

Phe Pro Gly Met Gly Ser Glu Glu Leu Arg Leu Ala Ser Phe Tyr Asp 85 90 95

Trp Pro Leu Thr Ala Glu Val Pro Pro Glu Leu Leu Ala Ala Gly 100 105 110

Phe Phe His Thr Gly His Gln Asp Lys Val Arg Cys Phe Phe Cys Tyr 115 120 Gly Gly Leu Gln Ser Trp Lys Arg Gly Asp Asp Pro Trp Thr Glu His 135 Ala Lys Trp Phe Pro Ser Cys Gln Phe Leu Leu Arg Ser Lys Gly Arg 150 Asp Phe Val His Ser Val Gln Glu Thr His Ser Gln Leu Leu Gly Ser 170 165 Trp Asp Pro Trp Glu Glu Pro Glu Asp Ala Ala Pro Val Ala Pro Ser 180 185 190 Val Pro Ala Ser Gly Tyr Pro Glu Leu Pro Thr Pro Arg Arg Glu Val 195 200 Gln Ser Glu Ser Ala Gln Glu Pro Gly Ala Arg Asp Val Glu Ala Gln 210 215 Leu Arg Arg Leu Gln Glu Glu Arg Thr Cys Lys Val Cys Leu Asp Arg 225 230 235 Ala Val Ser Ile Val Phe Val Pro Cys Gly His Leu Val Cys Ala Glu 245 250 Cys Ala Pro Gly Leu Gln Leu Cys Pro Ile Cys Arg Ala Pro Val Arg 260 265 Ser Arg Val Arg Thr Phe Leu Ser 275 280 <210> 2 <211> <212> PRT <213> Artificial Sequence <220> <223> HLA-A24 binding cancer antigen peptide derived from livin <400> 2

Ala Trp Asp His Val Asp Gly Gln Ile

```
1
<210> 3
<211> 10
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 3
Ala Trp Asp His Val Asp Gly Gln Ile Leu
                5
<210>
<211>
      10
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 4
Ala Phe Pro Gly Met Gly Ser Glu Glu Leu
<210> 5
<211>
      9
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 5
Gly Met Gly Ser Glu Glu Leu Arg Leu
                5
<210> 6
<211>
      9
<212>
      PRT
<213> Artificial Sequence
<220>
      HLA-A24 binding cancer antigen peptide derived from livin
<400> 6
Pro Trp Thr Glu His Ala Lys Trp Phe
```

```
<210>
      7
<211>
<212> PRT
<213> Artificial Sequence
<220>
       HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400> 7
Lys Trp Phe Pro Ser Cys Gln Phe Leu
<210>
      8
<211>
      10
<212>
      PRT
<213> Artificial Sequence
<220>
<223>
      HLA-A24 binding cancer antigen peptide derived from livin
<400> 8
Lys Trp Phe Pro Ser Cys Gln Phe Leu Leu
<210>
      9
<211>
      10
<212>
      PRT
<213> Artificial Sequence
<220>
       HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400> 9
Ala Lys Trp Phe Pro Ser Cys Gln Phe Leu
<210> 10
<211>
<212>
       PRT
<213> Artificial Sequence
<220>
      HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400> 10
Trp Phe Pro Ser Cys Gln Phe Leu Leu
```

```
<210>
      11
<211>
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 11
Arg Cys Phe Phe Cys Tyr Gly Gly Leu
<210>
      12
<211>
      9
<212>
      PRT
<213> Artificial Sequence
<220>
      HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400> 12
Leu Thr Ala Glu Val Pro Pro Glu Leu
<210> 13
<211>
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400>
      13
Val Gln Glu Thr His Ser Gln Leu Leu
                5
<210>
      14
<211>
      9
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 14
Ser Val Gln Glu Thr His Ser Gln Leu
```

```
<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 15
Gly Ala Arg Asp Val Glu Ala Gln Leu
                5
<210> 16
<211> 9
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 16
Thr Ala Glu Val Pro Pro Glu Leu Leu
<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 17
Gln Ile Leu Gly Gln Leu Arg Pro Leu
               5
<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 18
Asp Val Glu Ala Gln Leu Arg Arg Leu
<210> 19
```

```
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 19
Gly Pro Lys Asp Ser Ala Lys Cys Leu
<210> 20
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 20
Val Cys Ala Glu Cys Ala Pro Gly Leu
<210> 21
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 21
Val Pro Ala Ser Gly Tyr Pro Glu Leu
<210> 22
<211>
      9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 22
Phe Pro Gly Met Gly Ser Glu Glu Leu
<210> 23
<211> 9
```

```
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 23
Leu Ala Ser Phe Tyr Asp Trp Pro Leu
               5
<210> 24
<211> 9
<212> PRT
<213> Artificial Sequence
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 24
Ile Val Phe Val Pro Cys Gly His Leu
<210> 25
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 25
Ser Leu Gly Ser Pro Val Leu Gly Leu
<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 26
Glu Leu Leu Ala Ala Gly Phe Phe
               5
<210> 27
<211> 9
<212> PRT
```

```
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 27
Ala Thr Leu Ser Arg Gly Pro Ala Phe
<210> 28
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 28
His Gln Asp Lys Val Arg Cys Phe Phe
               5
<210> 29
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
     HLA-A24 binding cancer antigen peptide derived from livin
<400> 29
Leu Leu Arg Ser Lys Gly Arg Asp Phe
<210> 30
<211>
      9
<212> PRT
<213> Artificial Sequence
<220>
<223>
      HLA-A24 binding cancer antigen peptide derived from livin
<400> 30
Val Cys Leu Asp Arg Ala Val Ser Ile
               5
<210> 31
<211> 9
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 31
Gly Tyr Pro Glu Leu Pro Thr Pro Arg
               5
<210> 32
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 32
Ala Pro Gly Leu Gln Leu Cys Pro Ile
<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 33
Arg Ser Leu Gly Ser Pro Val Leu Gly Leu
               5
<210> 34
<211> 10
<212> PRT
<213> Artificial Sequence
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 34
Ser Val Gln Glu Thr His Ser Gln Leu Leu
                                   10
               5
<210> 35
<211> 10
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 35
Arg Leu Ala Ser Phe Tyr Asp Trp Pro Leu
<210> 36
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 36
Phe Tyr Asp Trp Pro Leu Thr Ala Glu Val
                5
<210> 37
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 37
Ser Val Pro Ala Ser Gly Tyr Pro Glu Leu
<210> 38
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 38
Met Gly Pro Lys Asp Ser Ala Lys Cys Leu
               5
<210> 39
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
```

```
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 39
Ser Ile Val Phe Val Pro Cys Gly His Leu
                5
<210> 40
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 40
Thr Gln Glu Arg Cys Gly Pro Arg Ser Leu
<210> 41
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223>
      HLA-A24 binding cancer antigen peptide derived from livin
<400> 41
His Ser Val Gln Glu Thr His Ser Gln Leu
                5
<210> 42
<211>
      10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 42
Cys Ala Glu Cys Ala Pro Gly Leu Gln Leu
<210> 43
<211>
      10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
```

```
<400> 43
Gly Gln Ile Leu Gly Gln Leu Arg Pro Leu
<210>
      44
<211>
      10
<212>
     PRT
<213> Artificial Sequence
<220>
      HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400>
     44
His Val Asp Gly Gln Ile Leu Gly Gln Leu
                5
<210>
      45
<211>
      10
<212> PRT
<213> Artificial Sequence
<220>
<223>
      HLA-A24 binding cancer antigen peptide derived from livin
      45
<400>
Leu Thr Ala Glu Val Pro Pro Glu Leu Leu
<210>
      46
<211>
      10
<212> PRT
<213> Artificial Sequence
<220>
<223>
      HLA-A24 binding cancer antigen peptide derived from livin
<400> 46
Gly Pro Arg Ser Leu Gly Ser Pro Val Leu
               5
<210> 47
<211>
      10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
```

```
<400> 47
Leu Val Cys Ala Glu Cys Ala Pro Gly Leu
                5
<210>
      48
<211>
       10
<212>
      PRT
<213> Artificial Sequence
<220>
       HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400>
      48
Gly Ser Glu Glu Leu Arg Leu Ala Ser Phe
<210>
      49
<211>
       10
<212>
      PRT
<213> Artificial Sequence
<220>
       HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400>
      49
Arg Ala Trp Asp His Val Asp Gly Gln Ile
                5
<210>
      50
<211>
      10
<212>
      PRT
<213>
      Artificial Sequence
<220>
      HLA-A24 binding cancer antigen peptide derived from livin
<223>
<400> 50
Ala Pro Val Arg Ser Arg Val Arg Thr Phe
<210>
      51
<211>
      10
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 51
```

```
Phe Leu Leu Arg Ser Lys Gly Arg Asp Phe
 <210> 52
 <211>
       10
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> HLA-A24 binding cancer antigen peptide derived from livin
 <400>
       52
 Cys Leu Asp Arg Ala Val Ser Ile Val Phe
                 5
 <210> 53
 <211>
       10
 <212>
       PRT
 <213> Artificial Sequence
 <220>
 <223>
       HLA-A24 binding cancer antigen peptide derived from livin
 <400> 53
 His Ala Lys Trp Phe Pro Ser Cys Gln Phe
                 5
 <210> 54
 <211>
       10
 <212>
       PRT
· <213> Artificial Sequence
 <220>
 <223>
       HLA-A24 binding cancer antigen peptide derived from livin
 <400> 54
 Asp Pro Trp Thr Glu His Ala Lys Trp Phe
                 5
 <210> 55
 <211>
       10
 <212>
       PRT
 <213> Artificial Sequence
 <220>
 <223> HLA-A24 binding cancer antigen peptide derived from livin
 <400> 55
```

```
Gly Ala Thr Leu Ser Arg Gly Pro Ala Phe
                5
<210> 56
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 56
Thr Gly His Gln Asp Lys Val Arg Cys Phe
                5
<210> 57
<211>
      10
<212>
      PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 57
Lys Val Cys Leu Asp Arg Ala Val Ser Ile
                5
<210> 58
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 58
Cys Ala Pro Gly Leu Gln Leu Cys Pro Ile
                5
<210> 59
<211>
      10
<212>
      PRT
<213> Artificial Sequence
<223> HLA-A24 binding cancer antigen peptide derived from livin
<400> 59
Arg Asp Val Glu Ala Gln Leu Arg Arg Leu
```

```
<210> 60
<211>
<212>
      PRT
<213> Artificial Sequence
<220>
<223> Peptide derived from EB virus
<400> 60
Thr Tyr Gly Pro Val Phe Met Ser Leu
<210> 61
<211>
      21
<212> PRT
<213> Artificial Sequence
<220>
<223> Tetanus toxin-originated helper peptide
<400> 61
Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
Ala Ser His Leu Glu
            20
<210> 62
<211>
      16
<212> PRT
<213> Artificial Sequence
<220>
<223> Helper epitope
<400> 62
Ala Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
                5
                                                       15
<210> 63
<211>
      10
<212> PRT
<213> Artificial Sequence
<220>
<223> Substitute-Type Peptide Derived From SEQ ID NO: 8
```

10

1

```
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Phe, Tyr, Met or Trp

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa is Phe, Leu, Ile, Trp or Met

<400> 63

Lys Xaa Phe Pro Ser Cys Gln Phe Leu Xaa
1 5 10
```

Docket No.: 520.40848CX1 Application No.: 10/730,108

Page 20 Art Unit: 2675

A display device according to claim 27, further 29. (Currently Amended) comprising a plurality of series combination combinations of a fourth PMISTFT and a fourth NMISTFT,

wherein said first junction point is disconnected from said output terminal of said level converter circuit,

said plurality of series combination combinations are cascaded in a plurality of stages,

a first terminal of said fourth PMISTFT of each of said plurality of series combination combinations is coupled to said high-voltage power supply line,

a second terminal of said fourth NMISTFT of each of said plurality of series combinations is coupled to said low-voltage power supply line,

gate terminals of said fourth PMISTFT and said fourth NMISTFT in a first one of said plurality of stages counting from said first junction point are coupled to said first junction point,

gate terminals of said fourth PMISTFT and said fourth NMISTFT in said plurality of stages excluding said first stage are coupled to junction points between a second terminal of said fourth PMISTFT and saida first terminal of said fourth NMISTFT of immediately preceding ones of said plurality of stages, and

a second junction point between a second terminal of said fourth PMISTFT and a first terminal of said fourth NMISTFT in a final one of said plurality of stages being connected to said output terminal of said level converter circuit.

30. (Original) A display device according to claim 27, wherein at least one of said first NMISTFT, said first PMISTFT, said second NMISTFT and said second

Docket No.: 520.40848CX1 Application No.: 10/730,108

Art Unit: 2675 Page 21

PMISTFT is substituted by one of a diode and a series combination of a diode and a resistor.

- 31. (Original) A display device according to claim 19, wherein said display device is a liquid crystal display device.
- 32. (Original) A display device according to claim 20, wherein said display device is a liquid crystal display device.
- 33. (Original) A display device according to claim 21, wherein said display device is a liquid crystal display device.
- 34. (Original) A display device according to claim 22, wherein said display device is a liquid crystal display device.
- 35. (Original) A display device according to claim 23, wherein said display device is a liquid crystal display device.
- 36. (Original) A display device according to claim 24, wherein said display device is a liquid crystal display device.
- 37. (Original) A display device according to claim 25, wherein said display device is a liquid crystal display device.

Application No.: 10/730,108 Docket No.: 520.40848CX1

Application No.: 10/730,106 Docket No.: 520.40646CX1

Art Unit: 2675 Page 22

38. (Original) A display device according to claim 26, wherein said display device is a liquid crystal display device.

39. (Original) A display device according to claim 27, wherein said display device is a liquid crystal display device.

40. (Original) A display device according to claim 28, wherein said display device is a liquid crystal display device.

41. (Original) A display device according to claim 29, wherein said display device is a liquid crystal display device.

42. (Original) A display device according to claim 30, wherein said display device is a liquid crystal display device.